PCR Biosystems Ltd

pcrbio.com

PCR Biosystems offers a range of best-in-class kits and reagents for real-time PCR, endpoint PCR and cDNA synthesis. Our reagents combine enhanced polymerases with highly developed reaction buffers and novel hot start chemistry to maximise yield and sensitivity from the simplest to most challenging of reactions. We continuously invest in research and development to bring innovative, high-performing products to market. Our products excel in yield, specificity, sensitivity and speed, giving your reaction the best chance of working as you want it to, first time.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MERCK AND ORNA THERAPEUTICS COLLABORATE TO ADVANCE ORNA’S NEXT GENERATION OF RNA TECHNOLOGY

Merck and Orna Therapeutics | August 17, 2022

news image

Merck known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA therapies, today announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck will make an upfront payment to Orna of $150 million, which will be expensed b...

Read More

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

news image

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

news image

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

news image

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More
news image

CELL AND GENE THERAPY

MERCK AND ORNA THERAPEUTICS COLLABORATE TO ADVANCE ORNA’S NEXT GENERATION OF RNA TECHNOLOGY

Merck and Orna Therapeutics | August 17, 2022

Merck known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA therapies, today announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck will make an upfront payment to Orna of $150 million, which will be expensed b...

Read More
news image

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More
news image

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More
news image

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More